Development of a highly potent anti-HBs monoclonal antibody for HBV and HDV therapy: An improvement with unsettled questions.
作者信息
Mouzannar Karim, Liang T Jake
机构信息
Liver Diseases Branch, National Institute of Diabetics and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
Liver Diseases Branch, National Institute of Diabetics and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
出版信息
J Hepatol. 2023 Nov;79(5):1079-1081. doi: 10.1016/j.jhep.2023.08.002. Epub 2023 Aug 15.
Abstract
摘要
相似文献
1
Development of a highly potent anti-HBs monoclonal antibody for HBV and HDV therapy: An improvement with unsettled questions.用于乙肝病毒和丁型肝炎病毒治疗的高效抗乙肝表面抗原单克隆抗体的研发：进展与待解问题
J Hepatol. 2023 Nov;79(5):1079-1081. doi: 10.1016/j.jhep.2023.08.002. Epub 2023 Aug 15.
2
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.强效广泛中和抗体VIR-3434可控制乙型和丁型肝炎病毒感染，并降低人源化小鼠中的乙肝表面抗原。
J Hepatol. 2023 Nov;79(5):1129-1138. doi: 10.1016/j.jhep.2023.07.003. Epub 2023 Jul 17.
3
Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections.当前和未来应用抗体被动免疫预防或控制 HBV/HDV 感染。
Antiviral Res. 2024 Jun;226:105893. doi: 10.1016/j.antiviral.2024.105893. Epub 2024 Apr 26.
4
Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients.维也纳 HIV+ 患者中 HBV 和 HDV 合并感染的流行病学趋势。
Liver Int. 2021 Nov;41(11):2622-2634. doi: 10.1111/liv.15018. Epub 2021 Aug 5.
5
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.REP 2139 和聚乙二醇干扰素 α-2a 治疗初治慢性乙型肝炎病毒和丁型肝炎病毒合并感染患者的安全性和疗效（REP 301 和 REP 301-LTF）：一项非随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28.
6
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection.一种用于预防和治疗慢性乙肝病毒（HBV）和丁型肝炎病毒（HDV）感染的抗乙肝表面抗原（HBsAg）人源单克隆抗体。
JHEP Rep. 2022 Dec 5;5(3):100646. doi: 10.1016/j.jhepr.2022.100646. eCollection 2023 Mar.
7
Hepatitis B Virus and Hepatitis D Virus Recurrence in Patients Undergoing Liver Transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus.乙型肝炎病毒和丁型肝炎病毒感染患者肝移植后乙型肝炎病毒和乙型肝炎病毒合并丁型肝炎病毒复发情况
Transplant Proc. 2016 Jul-Aug;48(6):2119-23. doi: 10.1016/j.transproceed.2016.02.076.
8
Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis.越南慢性乙型肝炎患者中 HBV 基因型 B 和 HDV 基因型 1 的优势。
Viruses. 2021 Feb 22;13(2):346. doi: 10.3390/v13020346.
9
Anti-HDV seroprevalance among patients with previous HBV infection.既往感染过乙肝病毒（HBV）的患者中丁型肝炎病毒（HDV）抗体血清流行率
North Clin Istanb. 2018 May 21;5(2):132-138. doi: 10.14744/nci.2018.01328. eCollection 2018.
10
Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population--how is the epidemiological situation?哥伦比亚人群中的乙型肝炎病毒（HBV）、丙型肝炎病毒（HCV）和丁型肝炎病毒（HDV）——流行病学情况如何？
PLoS One. 2011 Apr 29;6(4):e18888. doi: 10.1371/journal.pone.0018888.
本文引用的文献
1
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.强效广泛中和抗体VIR-3434可控制乙型和丁型肝炎病毒感染，并降低人源化小鼠中的乙肝表面抗原。
J Hepatol. 2023 Nov;79(5):1129-1138. doi: 10.1016/j.jhep.2023.07.003. Epub 2023 Jul 17.
2
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.慢性乙型和丁型肝炎临床治愈临床试验终点和研究设计指导：2022 年 AASLD-EASLHBV-HDV 治疗终点会议报告。
Hepatology. 2023 Nov 1;78(5):1654-1673. doi: 10.1097/HEP.0000000000000431. Epub 2023 Jun 21.
3
Hepatitis B.乙型肝炎
Lancet. 2023 Mar 25;401(10381):1039-1052. doi: 10.1016/S0140-6736(22)01468-4. Epub 2023 Feb 9.
4
Antibodies to combat viral infections: development strategies and progress.针对病毒感染的抗体：开发策略与进展。
Nat Rev Drug Discov. 2022 Sep;21(9):676-696. doi: 10.1038/s41573-022-00495-3. Epub 2022 Jun 20.
5
Hepatitis B: a new weapon against an old enemy.乙型肝炎：对抗宿敌的新武器。
Nat Med. 2021 Oct;27(10):1672-1673. doi: 10.1038/s41591-021-01512-5.
6
Hepatitis B virus - recent therapeutic advances and challenges to cure.乙肝病毒——近期的治疗进展与治愈面临的挑战
J Hepatol. 2020 Sep;73(3):694-695. doi: 10.1016/j.jhep.2020.04.015. Epub 2020 Jul 16.
7
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.全球丁型肝炎病毒感染的流行情况：系统评价和荟萃分析。
J Hepatol. 2020 Sep;73(3):523-532. doi: 10.1016/j.jhep.2020.04.008. Epub 2020 Apr 23.
8
Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection.重组人免疫球蛋白 Lenvervimab 治疗慢性乙型肝炎病毒感染的疗效。
Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1. doi: 10.1016/j.cgh.2019.09.038. Epub 2019 Oct 4.
9
Viral envelope-specific antibodies in chronic hepatitis B virus infection.慢性乙型肝炎病毒感染中的病毒包膜特异性抗体。
Curr Opin Virol. 2018 Jun;30:48-57. doi: 10.1016/j.coviro.2018.04.002. Epub 2018 May 5.
10
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.用进入抑制剂米鲁达宾治疗慢性丁型肝炎：Ib/IIa 期研究的初步结果。
J Hepatol. 2016 Sep;65(3):490-8. doi: 10.1016/j.jhep.2016.04.016. Epub 2016 Apr 27.
Zotero 插件